OGDEN CHRISTOPHER (See Remarks) received a stock award from CYTOMX THERAPEUTICS, INC.
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 2/4/2026ACC: 0001610717-26-000040
Officer· See Remarks
Since Feb 2022
+415K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
415K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+90K
Price / share
—
Trade value
—
% of position
39.8%
2/2/2026
226.27K→316.27K
Total
Net shares
+90K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/2/2026 | A · Award | +90K | — | — | 39.8% | 226.27K | 316.27K |
| Total | +90K | $0.00 | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
325K shares
Shares
+325K
Strike price
6.09
Held after
325K
Exercisable
—
2/2/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock325K shares | 2/2/2026 | A · Award | +325K | 6.09 | — | 325K |